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ARTICLE Clinical Trials 2013; 10: 709–719
Integrating biomarker information within trials
to evaluate treatment mechanisms and efficacy
for personalised medicine
Graham Dunna, Richard Emsleya, Hanhua Liua and Sabine Landaub
Background The development of personalised (stratified) medicine is intrinsically
dependent on an understanding of treatment-effect mechanisms (effects on thera-
peutic targets that mediate the effect of the treatment on clinical outcomes). There
is a need for clinical trial data for the joint evaluation of treatment efficacy, the utility
of predictive markers as indicators of treatment efficacy, and the mediational
mechanisms proposed as the explanation of these effects.
Purpose (1) To review the problem of confounding (common causes) for the draw-
ing of valid inferences concerning treatment-effect mechanisms, even when the data
have been generated using a randomised controlled trial, and (2) to suggest and
illustrate solutions to this problem of confounding.
Results We illustrate the potential of the predictive biomarker stratified design,
together with baseline measurement of all known prognostic markers, to enable us
to evaluate both the utility of the predictive biomarker in such a stratification and,
perhaps more importantly, to estimate how much of the treatment’s effect is actually
explained by changes in the putative mediator. The analysis strategy involves the
use of instrumental variable (IV) regression, using the treatment by predictive bio-
marker interaction as an IV – a refined, much more powerful, and (in the present
context) subtle use of Mendelian randomisation.
Conclusion Personalised (stratified) medicine and treatment-effect mechanisms
evaluation are inextricably linked. Stratification without corresponding mechanisms
evaluation lacks credibility. In the presence of mediator-outcome confounding,
mechanisms evaluation is dependent on stratification for its validity. Both stratifica-
tion and treatment-effect mediation can be evaluated using a biomarker stratified
trial design together with detailed baseline measurement of all known prognostic
biomarkers and other prognostic covariates. Direct and indirect (mediated) effects
should be estimated through the use of IV methods (the IV being the predictive mar-
ker by treatment interaction) together with adjustments for all known prognostic
markers (confounders) – the latter adjustments contributing to increased precision
(as in a conventional analysis of treatment effects) rather than bias reduction. Clinical
Trials 2013; 10: 709–719. http://ctj.sagepub.com
Introduction
After a predictive biomarker has met the necessary
development milestones, it is necessary to evaluate
its clinical utility through a confirmatory rando-
mised trial [1]. It is our strongly held view that the
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credibility of claims concerning the utility of a pre-
dictive biomarker depends on robust trials-based evi-
dence concerning both efficacy and treatment-effect
mechanisms – that is, on evidence provided by well-
designed Efficacy and Mechanisms Evaluation
(EME) trials. Although one might pursue the identi-
fication and validation of a predictive biomarker as a
separate objective to that of the evaluation of the
mediation of treatment effects (mechanisms evalua-
tion), we here make the case that pursuing them
together (1) provides more insight into any findings
arising through stratification on a predictive marker
(i.e., understand the mechanisms by which different
biomarker-based strata benefit from treatment) and
(2) enables consistent mechanisms evaluation (by
using the statistical interaction between predictive
marker and treatment as a strong instrumental vari-
able (IV) – to be explained below). Our aim in this
article is to explore in some detail how biomarker
information might be integrated into the design
and analysis of such an EME trial to both (1) demon-
strate substantial treatment-effect heterogeneity that
is indicated by the predictive biomarker and (2) eval-
uate the treatment-effect mechanisms that are
hypothesised to be the explanation for this treat-
ment-effect heterogeneity. The work does not
involve the development of new statistical metho-
dology, but the novelty of the approach comes from
its application in EME trials for the evaluation of
personalised medicines. We do not undervalue the
role of the traditional intention-to-treat (ITT) analy-
sis (efficacy evaluation), but emphasise that it
should be supplemented by robust evidence on
treatment-effect mechanisms.
EME
A b-blocker may be effective at reducing risk of
stroke in hypertensive patients, but its effect might
be greater in some patients than in others. Similarly,
it is likely to reduce average systolic blood pressure,
and again, its effect on average blood pressure is
likely to vary from one patient to another. It seems
self-evident (and consistent with biological theory)
that the b-blocker’s effect on risk of stroke is
explained by the fact that it reduces average blood
pressure. We might expect that if one individual’s
blood pressure has been lowered considerably more
than that of another individual, then the risk of
stroke is likely to have been reduced more in the
first person than in the second. But how might we
evaluate these claims in a clinical trial? How might
we estimate what portion of the b-blocker’s effect
on stroke is explained by its effect on average blood
pressure?
The rationale of the randomised clinical trial is
that it enables us to conclude that differences in
clinical outcomes observed in the randomised arms
are valid measures of the causal effects of treatment.
For simplicity, consider a randomised controlled
trial with two arms: treatment versus control. Also
for simplicity, we will assume that there is full
adherence to the allocated treatment (relaxing this
assumption does not affect the logic of our thesis,
but analysis as randomised is no longer evaluating
the effects of treatment receipt). Prior to randomisa-
tion to one of two competing treatment arms (sup-
posedly active drug versus placebo control, for
example) we can envisage two potential outcomes
for each participant in the trial – the outcome after
an active treatment, YA, say, and the outcome after
receiving the placebo, YP [2,3]. We can only ever
observe one of these two outcomes, dependent on
the treatment assignment mechanism, with the
other outcome being a counterfactual. However, in
principle, we can think of the effect of treatment as
a comparison of YA and YP – here, again for simpli-
city, we use the arithmetic difference, YA 2 YP. This
difference defines the Individual Treatment Effect
(ITE(Y)). We can never observe these individual
treatment effects, of course, but the random alloca-
tion ensures that we can estimate their average:
ATE(Y) =E(YA  YP)
=E(YA) E(YP)
=E(Y A)j E(Y P)j
The Average Treatment Effect, ATE(Y), defines the effi-
cacy of the active treatment with respect to the pla-
cebo control when the outcome of treatment is the
variable Y. Efficacy is evaluated and estimated by
comparison of the average of the outcomes in the
two arms. Returning to the individual treatment
effects, there is no reason to believe that they are the
same for all participants, and in fact, there is very
likely to be treatment-effect heterogeneity. This, of
course, is the underlying foundation of personalised
medicine.
In our randomised controlled trial, in addition to
measuring the clinical outcome of obvious impor-
tance to the patient and his or her clinician, we may
also choose to record the values of an intermediate
or proximal outcome, M, which, based on prior bio-
logical theory, is assumed to be a strong candidate
as a treatment-effect mediator (lowering systolic blood
pressure lowers stroke risk, blocking certain cell
receptors reduces rates of tumour growth, lowering
glycosylated haemoglobin in Type 2 diabetes lowers
risk of peripheral neuropathy, and so on). We
assume that there is an effect of treatment on the
mediator which, in turn, leads to an effect on the
clinical outcome. Again, we can define an individual
treatment effect for M, that is, ITE(M), and estimate
the corresponding efficacy, ATE(M). And, again,
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there is likely to be heterogeneity of the treatment
effects on the mediator, as well as those on the clini-
cal outcome itself.
Now we turn our attention to treatment-effect
mechanisms. If our intermediate outcome, M, is, in
fact, a mediator of the effect of treatment on clinical
outcome, Y, then we would expect that the effect of
treatment on M would provide us with an explana-
tion for its effect on Y. We are looking for more than
correlation (not just association). Not only would
the two effects be correlated but the effect on M
would be on a causal pathway between receipt of
treatment and final outcome. Complete mediation
would imply that the whole of the effect of treat-
ment on Y would be explained by its effect on M (all
of the treatment’s effect on Y would be through an
indirect path involving M; there would be no direct
causal link between treatment and clinical out-
come). More likely, however, is the fact that the
effect of treatment on Y is partly explained by its
effect via M; there is both a direct and an indirect
causal path between treatment and outcome. This
situation is represented graphically in Figure 2, and
we note that both M and Y are outcomes that are
indicators of response to treatment. What we wish
to refer to as a mediator (the proximal outcome) or
final outcome (distal to the mediator) depends upon
context. Before moving on to consider these path-
ways further, we digress to consider treatment-effect
heterogeneity in a bit more detail, particularly in
the context of the development of personalised
medicine.
Personalised medicine
Explicit notion of the heterogeneity of the causal
effect of treatment on outcome, and the search for
predictive markers that will explain this heterogeneity
and be useful in subsequent treatment choice, is at
the very core of what we here label as ‘Personalised
Medicine’. These so-called predictive markers can
arise through prior biological theory concerning
mediational mechanisms or through statistical
searches – but before they can be incorporated into a
large clinical trial to validate their use, the prelimin-
ary evidence for their predictive role needs to be
pretty convincing. If the predictive biomarker passes
this preliminary hurdle, our contention is that a large
trial of efficacy, designed to evaluate both treatment-
effect heterogeneity and corresponding mediational
mechanisms, will provide a richer and more robust
foundation for personalised or stratified therapy.
Types of biomarker
In the present context, we are primarily concerned
with the distinction between prognostic and
predictive markers (both assumed to be measured
prior to randomisation). Referring to measurements
made after the onset of treatment, the third type of
biomarker that would be potentially very useful is a
marker of treatment activity (i.e., the putative med-
iator). Here, we start with definitions provided by
Simon [4]: ‘A ‘‘prognostic biomarker’’ is a biological
measurement made before treatment to indicate
long-term outcome for patients either untreated or
receiving standard treatment’, and ‘A ‘‘predictive
biomarker’’ is a biological measurement made before
treatment to identify which patient is likely or unli-
kely to benefit from a particular treatment’. Let us
assume we are planning to run a placebo-controlled
drug trial: supposedly active drug versus inert pla-
cebo. Here, a prognostic marker would be a marker
whose average effects on patient outcome are identi-
cal in the two arms of the trial. A predictive marker
(or moderator [5]), in comparison, is associated with
differences in average treatment effect (it may also
be prognostic in the sense that it is associated with
outcome in both arms of the trial, but there would
be a need to include and estimate the size of marker
by treatment interactions in the model to describe
the treatment outcomes (but we need to be careful
to ensure that such an interaction is not simply a
result of using an inappropriate model/measure-
ment scale for the outcome). For example,
Overexpression of the HER2-neu gene in patients
with early breast cancer provides an example of a bio-
marker that has both prognostic value (patients with
HER2-neu overexpression having a worse prognosis)
and predictive value for herceptin (patients with
HER2-neu overexpression deriving a benefit from this
treatment). [6]
Graphical representations of the effects of prog-
nostic and predictive biomarkers are illustrated in
Figures 1(a) and 1(b), respectively.
Models for mediation
A simple graphical representation of treatment-
effect mediation is shown in Figure 2(a). Treatment
has an effect on the mediator which, in turn, has an
effect on the outcome (this is the indirect pathway).
Treatment also has a direct effect on outcome (i.e.,
that portion of the treatment’s effect that is not
explained by the postulated mediational mechan-
ism). However, Figure 2(a) is labelled as ‘naı¨ve’.
Why? In the critical appraisal of postulated causal
diagrams, one should always be very wary of what
might have been omitted. Omitted common causes
(hidden confounding) should always be considered
as a possible explanation for associations that might
be interpreted as causal. Random allocation of
Treatment mechanisms in personalised medicine 711
http://ctj.sagepub.com Clinical Trials 2013; 10: 709–719
 at Kings College London - ISS on January 27, 2016ctj.sagepub.comDownloaded from 
treatment (assuming, of course, complete adherence
to the treatment allocation) first rules out any com-
mon causes for treatment and the mediator and,
second, rules out any common causes for treatment
and the clinical outcome. But neither mediator nor
clinical outcome are under the direct control of ran-
domisation and there are very likely to be factors,
other than treatment, that have a common influ-
ence on these two outcomes of treatment. If we
were to assume that the model specified by Figure
2(a) is the correct one and analyse the data accord-
ingly (as described in the highly cited article by
Baron and Kenny [7], for instance), then we are very
likely to obtain misleading (biased) results if such
omitted common causes of mediator and outcome
do exist.
A more realistic model is represented by Figure
2(b). We have added the effects of the omitted pre-
randomisation variables (these are represented by
convention within an elliptical frame – indicating a
latent variable). Again, a key feature concerns con-
nections that are missing. There is no link between
the omitted variables and treatment, and specifi-
cally, there is no effect of treatment on any of these
omitted variables. How do we analyse our data to
estimate direct and indirect treatment effects when
assuming this model to be the correct one? Unfortu-
nately, we cannot, without incurring bias. If we only
have data on treatment allocation, and the values of
the two outcome measures (mediator and final out-
come), then we have a real problem. There is not
enough information contained in the data to allow
us to estimate the required treatment effects in the
presence of hidden confounding. Statisticians
describe this situation as an identifiability problem:
the model is said to be under-identified. In imple-
menting our trial, we need to collect more data –
and this is where biomarker measurements come in.
The potentially important roles of prognostic mar-
kers will be discussed in the sections ‘Using prognos-
tic markers for confounder adjustment’ and ‘Using
prognostic markers as IVs (Mendelian randomisa-
tion)’, and then we move on to discuss the even
more important role of predictive markers.
Before leaving this section, we admit to another
simplifying (‘naı¨ve’) assumption which is shared by
the Baron and Kenny model [7]. We are ignoring the
problem of measurement errors in the mediator and
the final outcome. This does not matter in the case
of the final outcome (except for lowering the preci-
sion of the estimated treatment effects), but mea-
surement errors in the mediator can lead to serious
Predictive
biomarker
Randomised
treatment
Outcome
(Response)
(b)
Prognostic
biomarker
Randomised
treatment
Outcome
(Response)
(a)
Figure 1. Graphical representations of the effects of prognostic
and predictive biomarkers: (a) prognostic biomarker and (b) pre-
dictive biomarker.
Black arrows indicate causal effects (the heavy lines being the ones of par-
ticular interest); the red arrow indicates moderation of the effect of treat-
ment on outcome.
(b)
Mediator
(mechanism)
Randomised
treatment
Final
outcome
Omitted
variables
Mediator
(mechanism)
(a)
Randomised
treatment
Final
outcome
Figure 2. Graphical representation of mediation: (a) the naı¨ve
model and (b) acknowledging hidden common causes
(confounders).
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biases. We will return to this potential complication
later when we show that the analytical solution of
the hidden confounding problem also deals with
those arising from random measurement errors in
the mediator.
Using prognostic markers for
confounder adjustment
Independent of treatment, baseline (pre-randomisa-
tion) prognostic markers are related to outcome. A
prognostic marker may have, and is likely to have,
an effect on both the intermediate and clinical out-
comes. If so, then it is a confounder. If we measure
and record the value of the prognostic variable, then
we are in a position to allow for its effects in our ana-
lyses. If we take measurements on several prognostic
biomarkers and other baseline covariates thought to
have prognostic value, then the resulting model is as
in Figure 3(a). In a two-stage analysis we first esti-
mate the effect of treatment on the mediator, adjust-
ing for all of our additional measurements (baseline
covariates and prognostic biomarkers), and then we
look at the joint effects of mediator and treatment
on outcome, again adjusting for all of our measured
confounders (baseline covariates and prognostic bio-
markers). This two-stage procedure will be valid if
and only if we have accounted for all of the com-
mon causes of M and Y. Otherwise the effects we are
attempting to estimate will suffer from residual con-
founding (residual biases). There may be baseline
markers that we might have measured, but have not
– we may be unaware of their existence, for instance
– and there are likely to be events (common causes)
influencing the participant once treatment has been
initiated (post-randomisation confounders – infec-
tions, bereavements, accidents and other life events;
co-morbid illness; additional medications; etc.). We
can never be sure.
Using prognostic markers as IVs
(Mendelian randomisation)
What if we have prior biological knowledge which
makes it highly plausible that a particular prognos-
tic marker has an effect on the mediator and,
although it is related to clinical outcome, it has no
direct effect on the clinical outcome? If this were
the case and the marker was also uncorrelated with
the omitted common causes, then such a prognostic
marker would be what is known as an IV or, in
short, an instrument. We do not wish to discuss any
of the technical details here, but such a situation
would enable us to use statistical techniques based
on IV models in order to obtain unbiased estimates
of the direct and indirect effects of treatment in the
presence of hidden confounding (including com-
mon causes arising post-randomisation). The IV
method also eliminates biases arising from random
measurement error in the putative mediator. The
avoidance of bias, however, comes at a cost. We are
losing precision when using IV methods. If the
prognostic biomarker were a genetic variant, then
this IV technique is an example of what has been
called Mendelian randomisation [8,9] – ‘Mendelian’
because we are dealing with genetic variation; ‘ran-
domisation’ because of the random assortment of
alleles during gamete formation. The causal model
involving a prognostic instrument – such as Mende-
lian randomisation – is illustrated in Figure 3(b)
Assuming that we are prepared to exchange lower
precision for lack of bias, why should we not decide
that we now have the solution? What are the limita-
tions of Mendelian randomisation in the context of
randomised trials for mechanisms evaluation? The
first is that in order to be of real practical value,
the instrument has to have a strong effect on the
(b)
Prognostic
Instrument 
Randomised
treatment
Prognostic
biomarkers 
Additional
baseline
covariates
Mediator
(mechanism)
Final
outcome 
Omitted
variables 
(a)
Randomised
treatment
Prognostic
biomarkers 
Additional
baseline
covariates 
Mediator
(mechanism) 
Final
outcome 
No omitted
variables? 
Figure 3. Making the most of the prognostic marker information:
(a) adjustment for all measured confounders (including prognos-
tic markers) and (b) introducing an instrumental variable (as in
Mendelian randomisation).
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putative mediator. In the context of a randomised
trial specifically focussing on an intervention target-
ing the proposed mediator, genes are likely to
explain very little of the within-treatment variability
of the mediator. This is the so-called weak instru-
ment problem [10,11]. If we have weak instrments,
the treatment-effect estimates are very imprecise,
and worse than that, they are inconsistent – they
are likely to be biased even with very large sample
sizes [10,11]. Another potential problem is that the
assumption of no direct effect of the genetic varia-
tion on clinical outcome (i.e., that there are no other
mediators of the treatment effect) may be untenable
[12]. We want to be fairly confident that our identi-
fying assumptions (those needed to allow us to esti-
mate the relevant treatment-effect parameters
without bias) are not obviously open to challenge.
In this context, it will be practically impossible to
verify them using the data at hand.
Using predictive markers to
generate IVs
Remembering that a predictive marker also has prog-
nostic properties, a predictive marker is likely to be a
confounder. In itself, it is unlikely to be a valid instru-
ment. But what about the treatment-effect modera-
tion (the treatment by marker interaction)? The very
essence of predictive (stratified) medicine is that
there is very strong moderation by the predictive
marker of the treatment effect on a supposedly
known target mechanism (mediator) and that the
moderating effect of predictive marker on the clinical
(distal) outcome is explained by treatment-induced
changes in the mediator. Accepting these conditions
(assumptions) is equivalent to stating that the treat-
ment by predictive marker interaction is an IV. This
is a strong assumption, always open to challenge, but
weaker and more easily defended than those needed
for Mendelian randomisation (see above). For exam-
ple, trastuzumab is a highly specific monoclonal
antibody targeted on the HER2-neu receptor protein,
and its efficacy is claimed to be moderated by the
genetic marker associated with variation in baseline
levels of the HER2-neu receptor. The assumption that
the treatment (trastuzumab) by genotype interaction
is a valid instrument seems eminently plausible. The
additional assumption that the HER2-neu genotype,
itself, does not have a direct effect on clinical out-
come is stronger, and may be much less plausible.
Let the binary treatment be represented by the
variable treat. Anticipating our simulated EME trial
(to be described below), let a binary predictive mar-
ker be X10 and the product of treat and X10 be X11.
The two causal (structural) models are
M =b0 +b1X10+b2treat +b3X11+ em ð1Þ
that is
E½M 1ð Þ M 0ð Þ=b2 +b3X10
Y =C0 +C1X10 +C2treat +C3M + ey ð2Þ
that is
E½(Y 1ð Þ  Y 0ð Þ)jX10=C2 +C3E½(M 1ð Þ M 0ð Þ)jX10
where em and ey are the random deviations (‘errors’)
associated with each of the two models, respectively.
We assume that these errors are correlated; that is,
cov(em, ey) 6¼ 0, acknowledging the fact that there are
missing common causes of M and Y. b2 is the effect
of treatment on the mediator (M) when X10 = 0. b3
is a measure of the strength of the effect on the med-
iator of the interaction between treatment and pre-
dictive biomarker. The effect of the treatment on the
mediator when X10 = 1 is the sum of b2 and b3. The
direct effect of treatment on outcome (Y) is the para-
meter c2, and the effect of the mediator on outcome
(irrespective of the levels of treatment and X10) is
c3. b1 and c1 are of no intrinsic interest but are
included to allow for the confounding explained by
the predictive marker, X10.
The total effect of treatment on outcome when
X10 = 0 is simply b2c3 + c2, and the proportion
explained by its effect on the mediator is b2c3/(b2c3
+ c2). Similarly, the total effect of treatment when
X10 = 1 is (b2 + b3)c3 + c2, and the proportion
explained by its effect on the mediator is (b2 +
b3)c3/((b2 + b3)c3 + c2).
Is our assumption that the interaction (X11) is a
valid IV justified? This depends on the strength of
the biological theory and the supporting evidence
for considering X10 to be a good predictive marker.
Is the interaction (X11) likely to be a weak instru-
ment? No. If it were a weak instrument (i.e., a weak
moderator) then we would suggest that it would
have already been discarded as a potentially useful
stratifying marker. For a predictive biomarker to
have met the necessary development milestones
implies that it is confidently assumed to be a power-
ful moderator of the effect of the treatment on the
proposed mediator. We are suggesting a refined,
much more powerful, and (in the present context)
useful version of Mendelian randomisation.
Taking equations (1) and (2) to represent the core
feature of an EME trial for a personalised treatment,
we now integrate all of our potential biomarker mea-
surements to suggest a viable trial design and asso-
ciated data analysis strategy.
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Putting it all together: a suggested
Biomarker Stratified Efficacy and
Mechanisms Evaluation (the BS-EME)
trial and associated analysis strategy
In the marker by treatment interaction design, we
stratify patients according to marker status and rando-
mise to treatments within each marker stratum [1].
An alternative phrase to describe this design is ‘bio-
marker stratified design’ [4,13]. We are concerned with
evaluating whether the treatment effects are the same
in the different strata. In the present context, our stra-
tifying biomarker is the binary variable, X10. Here, we
assume that we are planning a new trial but, of course,
the same principles might be applied to a retrospec-
tive analysis of archived trial data (or the meta-analy-
sis of individual patient data from several trials);
however, we would be pleasantly surprised if a rich-
enough data set was available for such an analysis.
Taking the biomarker stratified design as described
above, we supplement the baseline information
(i.e., X10 status) by measuring all previously vali-
dated prognostic markers (X1–X9, say) together
with baseline covariates (demographic information;
clinical and treatment history; co-morbidity; social,
psychological and cultural variables; and so on)
thought to have prognostic value. One obvious cov-
ariate is the baseline measurement of the putative
mediator. Another might be a baseline value for the
final outcome measurement. The rationale for all of
these measurements is (1) to allow for as much con-
founding of the effects of the mediator on final out-
come as is feasible, (2) to assess sensitivity of the
results to assumptions concerning residual hidden
confounding and, perhaps more importantly, and
(3) to increase the precision of the estimates of the
important causal parameters (as described in the sec-
tion ‘Using predictive markers to generate IVs’).
The graphical representation of the causal influ-
ences to be estimated from data arising from our
proposed design is shown in Figure 4. The two main
components of the model are (1) that for the com-
bined effects of treatment, markers and covariates
on the mediator (including the treatment by predic-
tive marker interaction), and (2) that for the com-
bined effects of treatment, mediator, markers and
covariates on the final outcome (but with no treat-
ment by predictive biomarker interaction). Again,
we bear in mind the hidden confounding. These
two regression models can be fitted simultaneously
with ease using two-stage least-squares (2sls) – a
so-called IV regression [14], available in most
general-purpose statistical software packages. Essen-
tially, we are simultaneously fitting our data to both
equations (1) and (2) after adjusting for all measured
confounders. We illustrate these analyses in the sec-
tion ‘Illustrative example: a simulated BS-EME trial’.
Illustrative example: a simulated
BS-EME trial
At this point, it would be nice to be able to illustrate
our ideas by reference to the analysis of data from a
real trial. Unfortunately, we are not aware of the
existence of trial(s) providing data along the lines
advocated here, and we do not have access to any
archived trial data that might be used as a suitable
illustration. In the United Kingdom, funding for
EME trials is a very recent innovation (http://
www.eme.ac.uk/) and few, if any of these trials have
reached completion. The application of EME metho-
dology to personalised medicine is in its infancy.
We are not aware of similar EME programmes in the
United States or elsewhere. Therefore, we have
resorted to a Monte Carlo simulation – the one big
advantage here being that we know the answers!
Both the simulation and the illustrative analyses
were carried out in Stata version 11 [15].
We simulate a relatively small trial with 100 partici-
pants randomly allocated to each of two arms. We
have baseline (pre-randomisation) measurements of
nine binary prognostic markers (X1–X9) on all parti-
cipants – genetic markers, say, with varying allele fre-
quencies (details are provided in the Appendix A). We
postulate a normally distributed quantitative media-
tor (M) and, similarly, a normally distributed indica-
tor of final outcome (Y). The presence of each of the
prognostic alleles coded as 1 increases both the med-
iator and the outcome by five units (i.e., these prog-
nostic markers are all confounders of the effect of M
on Y). We now introduce the randomised treatment
(treat), together with a binary (0/1) predictive
Predictive
biomarker 
Randomised
treatment
Prognostic
biomarkers 
Additional
baseline
covariates 
Mediator
(mechanism)
Final
outcome 
Omitted
variables
Figure 4. Using the predictive marker by treatment interaction as
an instrumental variable – using all available information (the BS-
EME trial).
BS-EME: Biomarker Stratified Efficacy and Mechanisms Evaluation.
The thick black pathways correspond to those treatment effects that we
wish to evaluate. The thick red pathway illustrates the moderating effect of
the predictive marker (assumed to only act through the effect of the treat-
ment on the mediator). The light dotted blue lines represent the effects of
both observed and hidden confounders.
Treatment mechanisms in personalised medicine 715
http://ctj.sagepub.com Clinical Trials 2013; 10: 709–719
 at Kings College London - ISS on January 27, 2016ctj.sagepub.comDownloaded from 
biomarker, X10, with the prevalence of the variant
coded as 1 being 20%, again measured prior to rando-
misation. As before, the product of X10 and treat,
X11, is the statistical interaction that measures the
strength of the moderation of the treatment effect by
X10. The marker X10 itself has a prognostic effect on
bothM and Y (i.e., it too is a confounder). If we allow
appropriately for X1–X11 in our statistical analyses of
the resulting data, there will be no hidden confound-
ing (no omitted variables effects).
Therefore, the statistical (causal) models used to
generate the data are
M =b0 +b1X10 +b2treat +b3X11
+Prognostic effects of X1 X9+ em
ð3Þ
Y =c0 +c1X10+c2treat +c3M
+Prognostic effects of X1 X9+ ey
ð4Þ
Full details are given in the Appendix A. Here, all
we need to know are the true values of b2 and b3,
and of c2 and c3. They are 5, 20, 10 and 2, respec-
tively. A value of 20 for b3 may appear to be unu-
sually high, but for a predictive biomarker to have
met the necessary development milestones implies
that is a powerful moderator of the effect of the
treatment on the proposed mediator. Summary sta-
tistics for this simulated trial are given in Table 1(a),
and the results of two simple regressions illustrating
the joint effects of treatment and predictive marker
on the two outcomes (M and Y, separately), together
with their expected (true parameter) values, are
shown in Table 1(b). Note that these estimates
obtained using models with no reference to the
prognostic markers, X1–X9, are not confounded –
we are simply looking at the ITT effects of randomi-
sation in the two strata determined by the values of
the predictive marker (X10). However, if we were to
adjust for the effects of X1–X9 in our analyses, then
there would be a gain in precision.
Returning to our true model (equations (3) and
(4)), when X10 = 0, the overall (total) effect of treat-
ment on final outcome (Y) is 20 units, and the
expected (true) proportion of the treatment effect on
Y that is explained by its effect onM (i.e., the indirect
effect of treatment) is (5 3 2)/20 3 100% = 50%.
When X10 = 1, the total effect is 60 units, and the
true proportion explained by treatment-induced
changes in M is (25 3 2)/60 3 100% = 83%. The
question we now pose is ‘What analysis do we need
to retrieve unbiased estimates of these effects?’ Esti-
mating the joint effects of treatment and X10 on M,
and of their interaction X11, is not a problem, even
in the absence of data on the prognostic markers.
Estimating the joint effects of treatment X10 and M
on the outcome, Y, however, is another matter. Table
2(a) shows the results of fitting the corresponding
regression models (the naı¨ve model – as in the Baron
and Kenny strategy [7]) in three situations. First (on
the left), we assume that we have no measures on
any of the prognostic markers (or we have chosen
not to use the data). Second (in the centre), we have
data on and have adjusted for four of them (X1–X4).
Finally (on the right), we have made adjustments for
the effects of all nine of prognostic markers. The
results on the left are clearly biased, and only some
of the bias has been corrected by allowance for
X1–X4. Without adjusting for any confounding, the
portions of the treatment effects explained by M are
69% and 92% when X10 = 0 and X10 = 1, respec-
tively. After adjusting for all nine confounders,
the estimated portions are 51% and 82%,
Table 1. A simulated BS-EME trial
(a) Summaries of the outcomes in our simulated trial: by predictive biomarker and treatment
Biomarker Treatment No. obs Mean (M) s.d. (M) Mean (Y) s.d. (Y)
0 No (0) 79 72.655 8.087 167.79 22.994
0 Yes (1) 80 77.732 8.449 188.5 22.402
1 No (0) 21 77.93 7.639 185.194 22.701
1 Yes (1) 20 103.21 6.866 244.025 18.213
(b) Standard regressions to test for interactions (the effect of X11)
Regress m X10 treat X11 Regress y X10 treat X11
Effect Expected* Estimate s.e. Expected* Estimate s.e.
X10 +5 +5.275 1.984 +15 +17.404 5.476
treat +5 +5.077 1.282 +20 +20.71 3.538
X11 (i.e., interaction) +20 +20.203 2.832 +40 +38.12 7.815
s. d.: standard deviation; s.e.: standard error; BS-EME: Biomarker Stratified Efficacy and Mechanisms Evaluation.
*From true parameter values.
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respectively – demonstrating that if we know all the
confounders and if we make adjustments for them
all, then we can retrieve the correct treatment effects.
So far, none of our analysis models for the joint
effects of M and treatment on the final outcome Y
have included a treatment by X10 interaction. Our
trial will have been designed on the assumption that
such an interaction does not exist. Our data have
here been simulated without this interaction. What
if we naı¨vely try to use our data to test whether this
interaction actually exists? The results of these ana-
lyses are shown in Table 2(b). The two naı¨ve analyses
reveal a highly statistically significant interaction.
This is an artefact of confounding. Only if we cor-
rectly allow for all of the known confounders (the
column on the right) do we obtain a small and sta-
tistically non-significant effect.
The use of familiar analyses based on multiple
regression has illustrated the problem of the con-
founding of the effect of the mediator on final out-
come. Only when we have measured and allowed
for all of the prognostic variables that explain this
confounding can we be confident in our results,
including an evaluation of whether there is a direct
effect of the treatment by predictive marker interac-
tion (X11) on the final outcome (i.e., whether X11
is a valid IV). In reality, even when we have col-
lected data on and allowed for all known confoun-
ders, we will not know whether there is any residual
confounding. Which is the safer assumption – (1)
there is no hidden confounding, or (2) there is no
direct effect of X11 on final outcome (X11 is a valid
instrument)? If our biological knowledge is as firm
as many investigators appear to claim it to be, then
we would be far more confident in (2).
Finally, assuming that X11 is indeed a valid IV, we
illustrate the use of IV regression (using 2sls, for
example) to analyse our data. The results are given
in Table 3: on the left without using X1–X9, and on
the right after allowing for X1–X9 as measured con-
founders. First, note the similarity of the estimates
from the two analyses. The validity of the simple
analysis on the left is not dependent on X1–X9. The
main difference is that after we allow for these vari-
ables, the standard errors of the estimates are con-
siderably lower (about 60% lower in this example).
This has implications for trial size and might make
the difference between a viable trial and one that is
not practically feasible. The IV regression without
covariates indicates that the portion of the treat-
ment effect on Y explained by its effect on M is 46%
and 81% when X10 = 0 and X10 = 1, respectively.
After adjustment for all covariates, the figures are
48% and 80%, respectively.
Comparing the results presented in Table 2 with
those in Table 3, it is clear that the IV estimates are
less precise, even in the situation where we have
adjusted for all of the confounders – in this latter
situation, the acknowledgement that there may be
hidden confounding (even though we know that in
Table 2. Multiple regression models for the joint effects of treatment and the mediator on outcome
(a) No interactions
Naı¨ve model (regress y
X10 treat m)
Adjustment for X1–X4
(regress y X10 treat m X1
X2 X3 X4)
Adjustment for all
confounders (regress y
X10 treat m X1 X2 X3 X4
X5 X6 X7 X8 X9)
Effect Expected* Estimate s.e. Estimate s.e. Estimate s.e.
X10 +5 21.643 1.493 +0.999 1.478 +6.009 1.286
treat +10 +5.613 1.119 +7.534 1.104 +11.859 0.971
M +2 +2.485 0.055 +2.334 0.059 +1.962 0.058
(b) Including a treatment by predictive marker interaction (i.e., the effect of X11)
Naı¨ve model (regress y
X10 treat m X11)
Adjustment for X1–X4
(regress y X10 treat m
X11 X1 X2 X3 X4)
Adjustment for all
confounders (regress y
X10 treat m X11 X1 X2
X3 X4 X5 X6 X7 X8 X9)
Effect Expected* Estimate s.e. Estimate s.e. Estimate s.e.
X10 +5 +3.474 1.622 +4.237 1.578 +6.449 1.355
treat +10 +7.302 1.070 +8.324 1.066 +2.013 0.971
M +2 +2.641 0.057 +2.497 0.067 +2.013 0.077
X11 215.231 2.552 211.890 2.621 22.516 2.440
*From true parameter values.
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this case there is not) is reflected in a less precise
estimate. In moving from ‘conventional’ regression
models involving adjustment for all measured con-
founders to the corresponding IV model, we assume
that we are reducing bias (correct if there is residual
hidden confounding), but we are reducing bias at
the cost of decreased precision. We suggest that trial
investigators specify one of the two approaches as
the primary analysis and then include the other one
as part of a secondary analysis of the sensitivity of
the findings to various model assumptions.
Technical issues
Readers interested in a more technical discussion of
the methods that can be used to estimate the direct
and indirect (mediated) effects of treatments in ran-
domised trials are referred to the relevant statistical
literature [16–22].
Conclusion
We conclude with a series of simple statements
aimed at encouraging trialists to seriously consider
the role of biomarkers that enable the simultaneous
evaluation of the utility of a putative predictive bio-
marker and the treatment-effect mechanisms moti-
vating its use.
1. Personalised (stratified) medicine and treat-
ment-effect mechanisms evaluation are inextric-
ably linked.
2. Stratification without corresponding mechan-
isms evaluation lacks credibility.
3. In the almost certain presence of mediator-out-
come confounding, mechanisms evaluation is
dependent on stratification for its validity.
4. Both stratification and treatment-effect media-
tion can be evaluated using a biomarker strati-
fied trial design together with detailed baseline
measurement of all known prognostic biomar-
kers and other prognostic covariates.
5. Direct and indirect (mediated) effects should be
estimated through the use of IV methods (the
IV being the predictive marker by treatment
interaction) together with adjustments for all
known prognostic markers (confounders) – the
latter adjustments contributing to increased pre-
cision (as in a conventional analysis of treat-
ment effects) rather than bias reduction.
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Appendix A
The Stata.do file to simulate a Biomarker
Stratified Efficacy and Mechanisms
Evaluation (BS-EME) trial (with two
variants of the predictive marker in
proportion 80:20)
program stratify
set obs 200
generate treat=0
replace treat=1 if _n.100
generate e1=uniform()
generate x1=0
replace x1=1 if e1.0.9
generate e2=uniform()
generate x2=0
replace x2=1 if e2.0.8
generate e3=uniform()
generate x3=0
replace x3=1 if e3.0.7
generate e4=uniform()
generate x4=0
replace x4=1 if e4.0.6
generate e5=uniform()
generate x5=0
replace x5=1 if e5.0.5
generate e6=uniform()
genenerate x6=0
replace x6=1 if e6.0.1
generate e7=uniform()
generate x7=0
replace x7=1 if e7.0.2
generate e8=uniform()
generate x8=0
replace x8=1 if e8.0.3
generate e9=uniform()
generate x9=0
replace x9=1 if e9.0.4
generate e10=uniform()
generate x10=0
replace x10=1 if e10.0.8
generate e12=50+5*invnorm(uniform())
generate x11=treat*x10
generate
m=5*x1+5*x2+5*x3+5*x4+5*x5+5*x6+5*x7
+5*x8+5*x9+5*x10+5*treat+20*x11+e12
generate e13=5*invnorm(uniform())
generate
y=5*x1+5*x2+5*x3+5*x4+5*x5+5*x6+5*x7
+5*x8+5*x9+5*x10+2*m+10*treat+e13
end
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